FSD Pharma Inc. announced the submission of the company's Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS, a candidate for the treatment of Multiple Sclerosis (MS). Lucid-MS is a first-in-class neuroprotective compound with a novel mechanism action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases. Preclinical evidence also showed that Lucid-MS promotes functional recovery in experimental animal models of MS.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2 CAD | 0.00% |
|
+5.26% | -83.33% |
Jun. 28 | FSD Pharma $2 Million Arbitration Award Upheld by Federal Court Against Former CEO | MT |
Jun. 28 | Sector Update: Health Care Stocks Decline in Late Afternoon Trading | MT |
1st Jan change | Capi. | |
---|---|---|
-83.33% | 7.01M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- HUGE Stock
- News FSD Pharma Inc.
- FSD Pharma Inc. Submits Its Phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation